Candel Therapeutics

Compare

387 Followers

CADL Stock Chart & Stats

$5.60

$0.00(0.00%)

At close: Jan 08 4:00 PM EST

$5.60

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$3.79 - $14.60

Previous CloseN/A

Volume524.53K

Average Volume (3M)820.22K

Market Cap

$296.43M

Enterprise Value$168.19M

Total Cash (Recent Filing)$100.69M

Total Debt (Recent Filing)$8.34M

Price to Earnings (P/E)―

Beta0.15

Next Earnings

Nov 06, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding54,895,100

10 Day Avg. Volume836,604

30 Day Avg. Volume820,224

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.57

Enterprise Value/Revenue168.19

Enterprise Value/Gross Profit-172.15

Enterprise Value/Ebitda-4.70

Forecast

1Y Price Target

$18.50

Price Target Upside230.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessA positive Phase 3 trial outcome from Candel’s CAN-2409 in the intermediate- to high-risk localized prostate cancer setting showed a 30% decrease in disease recurrence among the patients.

Market ExpansionCandel will initiate a Phase 3 trial for CAN-2409, expanding the revenue opportunity beyond the initial Prostate Cancer indication.

Regulatory ApprovalThere is a high likelihood that Candel’s CAN-2409 gains meaningful use in the clinic following a potential FDA approval.

Bears Say

Candel Therapeutics News

Candel initiated with an Overweight at Stephens on differentiated pipeline

As previously reported, Stephens initiated coverage of Candel Therapeutics (CADL) with an Overweight rating and $15 price target...

2d ago

CADL

Candel Therapeutics initiated with an Overweight at Stephens

Stephens initiated coverage of Candel Therapeutics (CADL) with an Overweight rating and $15 price target Published first on...

2d ago

CADL

Candel Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Candel Therapeutics (CADL) with an Outperform rating and $16 price target Published first...

9d ago

CADL

Candel Therapeutics appoints Pulendran to Candel’s RAB

Candel Therapeutics (CADL) announced the appointment of Bali Pulendran, Ph.D. to Candel’s Research Advisory Board, RAB. Dr. Pulendran...

14d ago

CADL

Candel Therapeutics enters into $130M term loan facility

Candel Therapeutics (CADL) entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN). The loan...

16d ago

CADL

TRIN

Candel Therapeutics announces interim data from phase 1b CAN-3110 trial

Candel Therapeutics (CADL) announced interim data from its ongoing phase 1b clinical trial of CAN-3110 in recurrent glioblastoma,...

16d ago

CADL

Trinity Capital provides $130M in growth capital to Candel Therapeutics

Trinity Capital (TRIN) announced the commitment of $130M in growth capital to Candel Therapeutics (CADL). Candel Therapeutics is...

16d ago

CADL

TRIN

Positive Buy Rating for Candel Therapeutics Driven by Promising Phase 3 Results of CAN-2409 and Strong Regulatory Prospects

Candel Therapeutics (CADL) has received a new Buy rating, initiated by LifeSci Capital analyst, Oliver McCammon. Oliver McCammon...

9d ago

CADL

Candel Therapeutics: Hold Rating Amid Promising Developments and Financial Uncertainty

Analyst Alec Stranahan from Bank of America Securities reiterated a Hold rating on Candel Therapeutics and keeping the...

15d ago

CADL

Candel Therapeutics Secures $130M Loan for Trials

The latest update is out from Candel Therapeutics ( ($CADL) ). On October 14, 2025, Candel Therapeutics announced...

16d ago

CADL

Promising Investment: Candel Therapeutics’ CAN-2409 Shows Efficacy in Prostate Cancer with Potential for Broader Applications

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Candel Therapeutics,...

23d ago

CADL

Promising Potential of Candel Therapeutics’ CAN-2409: A Versatile Immunotherapy with Broad Applicability

Analyst Andres Y. Maldonado of H.C. Wainwright reiterated a Buy rating on Candel Therapeutics, retaining the price target...

1M ago

CADL

Candel Therapeutics presents Phase 3 clinical trial of CAN-2409

Candel Therapeutics (CADL) “presented subgroup analyses focused on the radiation regimen from the Company’s positive phase 3 clinical...

1M ago

CADL

Candel Therapeutics downgraded to Neutral at BofA on lack of catalysts

As previously reported, BofA downgraded Candel Therapeutics (CADL) to Neutral from Buy with a price target of $7,...

2M ago

CADL

CADL FAQ

What was Candel Therapeutics’s price range in the past 12 months?

Candel Therapeutics lowest stock price was $3.79 and its highest was $14.60 in the past 12 months.

What is Candel Therapeutics’s market cap?

Candel Therapeutics’s market cap is $296.43M.

When is Candel Therapeutics’s upcoming earnings report date?

Candel Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 7 days.

How were Candel Therapeutics’s earnings last quarter?

Candel Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.164 by $0.074.

Is Candel Therapeutics overvalued?

According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Candel Therapeutics pay dividends?

Candel Therapeutics does not currently pay dividends.

What is Candel Therapeutics’s EPS estimate?

Candel Therapeutics’s EPS estimate is -0.19.

How many shares outstanding does Candel Therapeutics have?

Candel Therapeutics has 54,895,100 shares outstanding.

What happened to Candel Therapeutics’s price movement after its last earnings report?

Candel Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.164. Following the earnings report the stock price went down -5.625%.

Which hedge fund is a major shareholder of Candel Therapeutics?

Currently, no hedge funds are holding shares in CADL

Candel Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-55.18%

Trailing 12-Months

Asset Growth

300.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Candel Therapeutics (CADL) Earnings & Revenues

Historic Earnings Reports

CADL Stock 12 Month Forecast

Average Price Target

$18.50

▲(230.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","-1":"-$1","5.75":"$5.75","12.5":"$12.5","19.25":"$19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5.75,12.5,19.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.54,7.0369230769230775,8.533846153846154,10.03076923076923,11.527692307692309,13.024615384615384,14.521538461538462,16.01846153846154,17.515384615384615,19.012307692307694,20.50923076923077,22.006153846153847,23.503076923076925,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.54,6.5369230769230775,7.533846153846154,8.53076923076923,9.527692307692309,10.524615384615384,11.521538461538462,12.51846153846154,13.515384615384615,14.512307692307694,15.509230769230768,16.506153846153847,17.503076923076925,{"y":18.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.54,5.6523076923076925,5.764615384615385,5.876923076923077,5.989230769230769,6.101538461538461,6.213846153846154,6.326153846153846,6.438461538461539,6.55076923076923,6.663076923076924,6.775384615384615,6.887692307692308,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.9,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.28,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >